Recent Posts in ‘Featured Companies’
Clinical Trials Provide Catalyst for AtheroNova (AHRO)
Lipid regulating drugs, generally statins, are the steady leader amongst the most widely prescribed drugs each year in the United States. Lipid regulators, such as Pfizer Inc.’s (NYSE: PFE) blockbuster Lipitor and AstraZeneca PLC’s (NYSE: AZN) Crestor, are used to control high blood cholesterol and get dished-out to patients virtually like nothing else. Even antidepressants
Athersys (ATHX) Reports Progress in Phase 2 Study of MultiStem for Ischemic Stroke
There are many areas of unmet medical need across the planet, but stroke is arguably one of the most debilitating traumas for which an efficient, effective treatment is currently lacking. The reality is that traditional drugs are not the answer for the roughly 2 million people each year in the United States, Europe and Japan
SpectraScience (SCIE) Completes WavSTAT4 Installation and Training with PENTAX in Europe
SpectaScience Inc. (OTCBB: SCIE), a developer of light-based diagnostic technology for cancer identification, similar to companies like Verisante Technology Inc. (CVE: VRS) and MELA Sciences Inc. (NASDAQ: MELA), recently completed its WavSTAT4 installation and training under its distribution agreement with PENTAX in Europe. Investors are hoping that the move paves the way for near-term revenues
Cardium (CXM) to Present at Rodman & Renshaw Healthcare Investment Conference
Cardium Therapeutics (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR),
SpectraScience (SCIE) and PENTAX: Three Indicators Why this Agreement is a Big Deal
SpectraScience Inc. (OTCQB: SCIE), a developer of light-based diagnostic technology for cancer identification, similar to companies like Verisante Technology Inc. (CVE: VRS) and MELA Sciences Inc. (NASDAQ: MELA), recently announced a very significant agreement with PENTAX that the market seems to have largely dismissed. As a result, the stock appears to be trading at a
OxySure (OXYS) Improves Bottom Line as It Ramps Up Revenues
OxySure Systems Inc. (OTCBB: OXYS), a medical technology company focused on the design, manufacture and distribution of specialty medical and respiratory solutions, similar to companies like Medtronic, Inc. (NYSE: MDT) and St. Jude Medical, Inc. (NYSE: STJ), recently reported its second quarter financial results. Digging a little deeper into the company’s latest quarterly report shows
Cardium Reports on Recent Developments
Cardium Therapeutics Ltd. (NYSE MKT: CXM), an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and business with the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR),
Athersys to Host Second Quarter 2012 Financial Results Call
Athersys, Inc. (ATHX) recently announced it will release its second quarter 2012 financial results at approximately 4:00 PM (Eastern Time) on Monday, August 13, 2012, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and
Pressure BioSciences’ Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Advantages of the PCT Platform Could Potentially Enhance Development of New Products in the Forensic, Environmental, and Biodefense Areas, and in the Discovery of Biomarkers of Disease Pressure BioSciences, Inc. (OTCQB: PBIO), a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), providing equipment to companies like
Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
Company Reiterates Guidance for Continued Strong Revenue Growth Throughout 2012 as its PCT Products Commercialization Plan Unfolds Pressure BioSciences, Inc. (OTC:PBIO) has developed patented technology that could significantly change and improve the way biological sample preparation is done. Having spent the last several years developing the products and garnering widespread recognition from the scientific community,
Pressure BioSciences (PBIO): Favorable Financing and Board Changes Signal Commercialization, Progress
Pressure BioSciences, Inc. (OTCQB: PBIO) is a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), which it provides to companies like Thermo Fisher Scientific (NYSE: TMO), Amgen Inc. (NASDAQ: AMGN) and other medical and biotechnology companies around the world. We have been following them for some
Cardium (CXM) Announces Latest Nutra-App and Sponsorship of Olympic Qualifier
Cardium Therapeutics (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, offering product lines similar to companies such as Nutraceutical International Corp (NASDAQ: NUTR) and Schiff Nutrition